| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Colao, A Cuocolo, P Marzullo, E Nicolai, D Ferone, A M Della Morte, R Pivonello, M Salvatore, G Lombard. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. The Journal of clinical endocrinology and metabolism. vol 86. issue 4. 2001-05-03. PMID:11297582. |
these results strengthen the need of a stable suppression of gh and igf-i hypersecretion to restore a normal cardiac performance in acromegaly. |
2001-05-03 |
2023-08-12 |
human |
| G A Kaltsas, A M Isidori, D Florakis, P J Trainer, C Camacho-Hubner, F Afshar, I Sabin, J P Jenkins, S L Chew, J P Monson, G M Besser, A B Grossma. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. The Journal of clinical endocrinology and metabolism. vol 86. issue 4. 2001-05-03. PMID:11297598. |
acromegaly is associated with increased morbidity and mortality unless serum gh levels are persistently less than 5 mu/l ( approximately 2 ng/ml) after treatment. |
2001-05-03 |
2023-08-12 |
Not clear |
| R J Ross, K C Leung, M Maamra, W Bennett, N Doyle, M J Waters, K K H. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. The Journal of clinical endocrinology and metabolism. vol 86. issue 4. 2001-05-03. PMID:11297608. |
the gh receptor antagonist, b2036-peg, has been developed for treating acromegaly. |
2001-05-03 |
2023-08-12 |
Not clear |
| P Cohen, D R Clemmons, R G Rosenfel. Does the GH-IGF axis play a role in cancer pathogenesis? Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 10. issue 6. 2001-04-19. PMID:11161960. |
the role of gh in cancer initiation is further negated by the fact that in acromegaly, the incidence of cancer, other than possibly colonic neoplasia does not appear to be significantly increased. |
2001-04-19 |
2023-08-12 |
mouse |
| J A Beentjes, A van Tol, W J Sluiter, R P Dullaar. Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis. vol 153. issue 2. 2001-04-19. PMID:11164439. |
growth hormone (gh) deficiency and acromegaly may be associated with increased cardiovascular risk. |
2001-04-19 |
2023-08-12 |
human |
| A Colao, P Marzullo, C Di Somma, G Lombard. Growth hormone and the heart. Clinical endocrinology. vol 54. issue 2. 2001-04-19. PMID:11207626. |
however, several lines of evidence have suggested that the cardiovascular abnormalities can be partially reversed by suppressing gh and igf-i levels in acromegaly or after gh replacement therapy in ghd patients. |
2001-04-19 |
2023-08-12 |
Not clear |
| S R Peacey, A A Toogood, J D Veldhuis, M O Thorner, S M Shale. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. The Journal of clinical endocrinology and metabolism. vol 86. issue 1. 2001-04-12. PMID:11232010. |
in patients with treated acromegaly, improved survival is associated with serum gh concentrations below 2 microgram/l (5 mu/l). |
2001-04-12 |
2023-08-12 |
human |
| S R Peacey, A A Toogood, J D Veldhuis, M O Thorner, S M Shale. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. The Journal of clinical endocrinology and metabolism. vol 86. issue 1. 2001-04-12. PMID:11232010. |
a principal aim of therapy in acromegaly is to achieve a gh level less than 2 microgram/l, as such levels are thought to be "safe." |
2001-04-12 |
2023-08-12 |
human |
| S R Peacey, A A Toogood, J D Veldhuis, M O Thorner, S M Shale. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. The Journal of clinical endocrinology and metabolism. vol 86. issue 1. 2001-04-12. PMID:11232010. |
in the acromegaly group a significant positive correlation was found between igf-i and the calculated gh secretory burst amplitude in the radiotherapy subset (r = 0.85; p < 0.0005) as well as between igf-i and both the mean gh valley nadir (r = 0.60; p < 0.004) and the trough (oc 5%) gh activity for the acromegalic patients as a whole (r = 0.55; p < 0.02). |
2001-04-12 |
2023-08-12 |
human |
| S R Peacey, A A Toogood, J D Veldhuis, M O Thorner, S M Shale. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. The Journal of clinical endocrinology and metabolism. vol 86. issue 1. 2001-04-12. PMID:11232010. |
we conclude that in treated acromegaly (gh, <2 microgram/l), 1) igf-i (by approximately 50%) and basal gh secretion (by 5-fold) remain significantly elevated compared with control values despite similar mean 24-h gh concentrations; 2) the calculated gh secretory pulse amplitude, mean gh valley nadir, and oc 5% correlate positively with igf-i; 3) the greater mean gh valley nadir and oc 5% in acromegalic patients compared with controls may account for the raised igf-i; and 4) radiotherapy is unlikely to normalize the gh secretory pattern, which underlies the persisting elevated igf-i levels. |
2001-04-12 |
2023-08-12 |
human |
| J J Díez, P Iglesia. Current management of acromegaly. Expert opinion on pharmacotherapy. vol 1. issue 5. 2001-04-05. PMID:11249504. |
acromegaly, a chronic disease of growth hormone (gh) hypersecretion, is most typically caused by a pituitary adenoma. |
2001-04-05 |
2023-08-12 |
Not clear |
| J J Díez, P Iglesia. Current management of acromegaly. Expert opinion on pharmacotherapy. vol 1. issue 5. 2001-04-05. PMID:11249504. |
dopamine agonists bind to the d2 receptor and suppress gh hypersecretion in some patients with acromegaly. |
2001-04-05 |
2023-08-12 |
Not clear |
| J J Díez, P Iglesia. Current management of acromegaly. Expert opinion on pharmacotherapy. vol 1. issue 5. 2001-04-05. PMID:11249504. |
somatostatin analogues have been shown to improve clinical symptoms of acromegaly, decrease hypersecretion of gh and igf-i and reduce tumour volume in a clinically significant number of patients. |
2001-04-05 |
2023-08-12 |
Not clear |
| K C Tan, A W Tso, K S La. Effect of Sandostatin LAR on serum leptin levels in patients with acromegaly. Clinical endocrinology. vol 54. issue 1. 2001-03-29. PMID:11167923. |
serum leptin levels are decreased in patients with acromegaly and rise after gh is normalized by surgical treatment. |
2001-03-29 |
2023-08-12 |
Not clear |
| K C Tan, A W Tso, K S La. Effect of Sandostatin LAR on serum leptin levels in patients with acromegaly. Clinical endocrinology. vol 54. issue 1. 2001-03-29. PMID:11167923. |
leptin concentrations were decreased in patients with active acromegaly and lowering gh by either sandostatin lar or transsphenoidal surgery led to an increase in leptin concentrations. |
2001-03-29 |
2023-08-12 |
Not clear |
| R D Murray, S R Peacey, A Rahim, A A Toogood, M O Thorner, S M Shale. The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients. Clinical endocrinology. vol 54. issue 1. 2001-03-29. PMID:11167924. |
furthermore, gh secretagogues may have a role, in combination with serum igf-i levels, in the diagnosis of gh deficiency in treated acromegaly. |
2001-03-29 |
2023-08-12 |
Not clear |
| E M Erfurth, B Bülow, L E Hagma. Is vascular mortality increased in hypopituitarism? Pituitary. vol 3. issue 2. 2001-03-08. PMID:11141699. |
in all four studies patients with acromegaly or cushing's disease were excluded, and patients with gh replacement were not included. |
2001-03-08 |
2023-08-12 |
Not clear |
| A Sartorio, M Cattaneo, P Bucciarelli, B Bottasso, S Porretti, P Epaminonda, G Faglia, M Arosi. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 108. issue 7. 2001-03-01. PMID:11083070. |
alterations of coagulation and fibrinolytic systems might contribute to the increased cardiovascular and cerebrovascular mortality observed in patients with both chronic growth hormone (gh) excess (acromegaly) and deficiency (ghd). |
2001-03-01 |
2023-08-12 |
human |
| A Sartorio, M Cattaneo, P Bucciarelli, B Bottasso, S Porretti, P Epaminonda, G Faglia, M Arosi. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 108. issue 7. 2001-03-01. PMID:11083070. |
to assess the importance of gh in modulating haemostatic system, several haemostatic variables in patients with ghd and acromegaly were measured. |
2001-03-01 |
2023-08-12 |
human |
| M Volterrani, F Manelli, M Cicoira, R Lorusso, A Giustin. Role of growth hormone in chronic heart failure. Therapeutic implications. Drugs. vol 60. issue 4. 2001-03-01. PMID:11085197. |
patients with acromegaly have an increased propensity to develop ventricular hypertrophy and cardiovascular diseases and, in addition, an impaired cardiac efficiency is observed in patients with gh deficiency. |
2001-03-01 |
2023-08-12 |
Not clear |